FOR ADVISORS

Partner with Bioverge to empower your clients.

Bioverge's premier healthcare venture capital investment platform lets you offer your clients the same opportunities as some of the best-known institutional investors in the world.

Contact Us

Performance that
speaks for itself.

OUR PERFORMANCE AS OF 03/311/2023
Select Exited Investments
Testimonial Image

Solis at Winter Park

Winter Park, FL  •  Multifamily

Size

389 unit

Acquisition Date

Sep 2018

Purchase Price

$79M

Underwritten Net IRR

11.2 %

Solis at Winter Park

Winter Park, FL  •  Multifamily

Size

389 unit

Acquisition Date

Sep 2018

Purchase Price

$79M

Underwritten Net IRR

11.2 %

Testimonial Image

Solis at Winter Park

Winter Park, FL  •  Multifamily

Size

389 unit

Acquisition Date

Sep 2018

Purchase Price

$79M

Underwritten Net IRR

11.2 %


Current client? Welcome back! Log in here.

Efficient access to premier healthcare investments.

Invest in specific healthcare deals or managed portfolios. Bioverge partners with family offices, individuals, and advisors like you.
Access Funds
A one-and-done portfolio of emerging startups at the intersection of healthcare + technology — each managed by our experienced investment professionals.
Deal-By-Deal
Build a bespoke healthcare startup portfolio, one investment at a time, from a selection of institutional-quality opportunities.
Thematic Funds
Similar to Access Funds, but focused on specific technology or disease areas such as longevity, cancer, digital health, and more.

Current client? Welcome back! Log in here.

Bioverge invests alongside leading institutional investors.

Investing with Bioverges, means you're investing alongside top-tier venture capital firms, at the same terms.
Current client? Welcome back! Log in here.

What Bioverge brings to you.

Advisors

Experienced team of investment professionals
Established network of subject matter experts and operators
Transparent due diligence on each investment opportunity
Comprehensive performance reporting and quarterly updates.
Control over presentation of information to clients

Clients

Attractive fees compared to traditional institutional-quality healthcare venture capital funds
Bespoke portfolio construction based on your investment objectives
Favorable tax implications, including long-term capital gains and QSBS eligible investmenst
Curated healthcare deals at both an individual SPV and fund level
Visibility into performance through our platform if or when desired

Essential diversification and effective wealth generation.

Investors are increasingly demanding access to the private markets.
Bioverge is here to help you have that conversation.
Why Venture Capital?
Venture capital has historically generated outsized returns and become a staple of diversified, professional investment portfolios. If you’re not investing in venture capital, you may be leaving money on the table. Answer just a few qualifying questions to join our community of investors and you could change your financial trajectory.
Why Bioverge?
We enable you to invest in startups that are transforming healthcare and directly impact the causes you care about most. Leveraging our deep domain expertise and expansive network, we provide you access to premier healthcare startups and offer specialized support to our growing portfolio.
Why Now?
The life sciences revolution is the venture capital opportunity of our lifetimes. At the convergence of healthcare + technology, unprecedented innovation is unfolding that stands to radically reshape and transform the future of medicine over coming decades.

Current client? Welcome back! Log in here.

Our latest insights and outlooks.

View All
Footnotes
1 Data as of March 31, 2023. Accredited Investors is based on accredited investors in the Bioverge Network. Realized Net IRR (internal rate-of-return) is net of fees and expenses. MOIC (multiple-on-invested capital) is gross, before taking into account fees and expenses. Realized Net IRR and Realized MOIC are realized values based on the performance of all exits and write-downs or liquidation events, and are limited to companies within our portfolio that have had an exit event or have been shut down, or are otherwise no longer operating. Realized Net IRR and Realized MOIC are based on distributions calculated at the time of transaction close, and include escrows and amounts receivable at a future date but do not include contingent compensation that may not be realized. Realized Net IRR and Realized MOIC may be higher or lower due to the impact of market fluctuations for publicly held securities and the impact of the timing of distributions. Results are not audited. Past performance is not indicative of future results.  Back
Important Disclosures
Private Securities
Investments in private offerings are speculative and involve a high degree of risk. Investments in private offerings are not bank deposits and therefore are not insured by the FDIC or guaranteed by any other party. Investors must be qualified as an accredited investor to participate in private offerings and you may be required to verify your status as an accredited investor. No securities commission or regulatory authority has recommended or approved any investment or the accuracy or completeness of any of the information or materials provided by or through us.
Not Advice
This communication is not to be construed as investment, tax, or legal advice in relation to the relevant subject matter; investors must seek their own legal or other professional advice before making any investment to determine whether an investment is suitable for them.
Performance Not Guaranteed
Past performance is no guarantee of future results. Any historical returns, expected returns, or probability projections are not guaranteed and may not reflect actual future performance.
Risk of Loss
All investments involve a high degree of risk and may result in partial or total loss of your investment.
Liquidity Not Guaranteed
Investments offered by Bioverge are illiquid and there is never any guarantee that you will be able to exit your investments on the Secondary Market or at what price an exit (if any) will be achieved.
Not an Offer to Sell or Solicitation to Buy
The information presented on this Website does not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of the securities of Bioverge. Any such offer would only be made through of a prospectus, private placement memorandum, subscription agreement or similar documents. This Website is subject to material updating, revision and further amendment.
Conduct Your Own Due Diligence
This information is not intended to provide the sole basis for your evaluation of Bioverge. You should conduct your own due diligence of Bioverge and independently verify the information contained below before proceeding further with any investment in or other transaction with Bioverge. Our officers will make themselves available to answer any questions that you may have regarding our company, its business, operations and prospects should you decide to proceed further with an investment or other transaction with Bioverge.
Forward Looking Statements
The information set forth below includes statements, estimates, projections with respect to our anticipated future performance and other forward-looking statements, which are subject to risks, uncertainties and assumptions. In some cases, you can identify these statements by forward-looking words such as “may”, “might”, “will”, “should”, “expect”, “plan”, “anticipate”, “believe”, “estimate”, “predict”, “potential”, “future” or “continue”, the negative of these terms and other comparable terminology. Such forward-looking statements are based on current plans, estimates and expectations and are made pursuant to the Private Securities Litigation Reform Act of 1995. These statements, estimates and projections are based upon various assumptions that we made concerning our anticipated results and industry trends, which may or may not occur. We are not making any representations as to the accuracy of these statements, estimates or projections. Our actual performance may be materially different from the statements, estimates or projections set forth below. We are under no duty to update any of these forward-looking statements to conform them to actual results or revised expectations. Back